Uppsala, Sweden and Southport, N.C., July 10, 2018: Gyros Protein Technologies AB, a pioneer in automated nanoliter-scale immunoassays and leading provider of peptide synthesizers and reagents, and Cygnus Technologies, the leading assay and services provider for the detection and characterization of impurities in biopharmaceuticals, today announced they have signed a licensing and supply agreement.
Under the agreement, Cygnus Technologies will supply Gyros Protein Technologies with its proprietary reagents for host cell protein analysis, enabling the development of new Gyrolab® immunoassay kits and applications to further support customers working in biotherapeutics development and manufacturing. Gyros Protein Technologies has established expertise in bioprocess development, through its Gyrolab platforms and Gyrolab ready-to-use kits for CHO-HCP, Protein A impurity analyses, and IgG titer determinations. Gyrolab users carrying out impurity analysis will now also benefit from the products and expertise provided by Cygnus Technologies.
As the global leader in ELISA kits for bioprocess impurity analysis, Cygnus Technologies will also assist Gyrolab users in developing custom, process-specific antibodies, or in running orthogonal methods for antibody and impurity characterization.
Dan Calvo, CEO and president,Gyros Protein Technologies said: “The agreement with Cygnus Technologies forms part of our strategy to continue to support customers with high quality bioanalytical solutions, and to increase productivity in the development and manufacturing of biotherapeutics. Cygnus Technologies’ offering complements our current portfolio, and the partnership will enable us to increase our support to bioprocess customers.”
Ken Hoffman, president of Cygnus Technologies, said: “This collaboration with Gyros Protein Technologies will give customers looking for automated solutions the opportunity to automate our well-characterized antibodies and antigens on the Gyrolab platforms. Those same customers can also access custom antibody services along with state-of-the-art orthogonal analytical methods developed at Cygnus Technologies.”
ENDS
Notes to editors
Media contacts:
For Gyros Protein Technologies:
Katie Odgaard
Zyme Communications
Tel: +44(0)7787 502 947
Email: katie.odgaard@zymecommunications.com
For Cygnus Technologies (part of Maravai Lifesciences):
David Weber
Tel: +1-650-292-2674
Email: david.weber@maravai.com
About Gyros Protein Technologies
Gyros Protein Technologies, enables peptide synthesis and bioanalytical solutions that help scientists increase biomolecule performance and productivity in research, drug discovery, pre-clinical and clinical development, and bioprocess applications. Our low- to mid-scale peptide synthesizer platforms are the Tribute®, Prelude® X, Symphony® X, and Sonata®. These solutions and our chemistries deliver uncompromising purity, flexibility, and quality for discovery and pre-clinical studies of simple to complex multifunctional peptides. Proprietary high-performance nanoliter-scale immunoassay platforms, Gyrolab® xPand, Gyrolab® xP workstation and Gyrolab xPlore™, are used by scientists in leading pharmaceutical, biotech, CRO, and CMO companies for bioanalytical applications such as pharmacokinetics/pharmacodynamics, immunogenicity, and quantitating bioprocess-related impurities. Our peptide synthesis and bioanalytical solutions accelerate your discovery, development, and manufacturing of safer biotherapeutics.
About Cygnus Technologies
Cygnus Technologies develops, manufactures and markets assay kits and related services that enable pharmaceutical and biotech companies to detect and identify host cell impurities in biotherapeutics, an important step in regulatory approval and quality control processes. With products, services and expert advice, Cygnus helps biopharmaceutical companies move new therapeutics more quickly through the development and approval stages to market.
With headquarters in Southport, N.C., Cygnus Technologies serves customers worldwide through a global distributor network. Cygnus Technologies is part of Maravai LifeSciences, a life sciences reagent company committed to catalyzing the growth of successful, entrepreneurial life science companies by providing expertise, capital, processes and systems so that they can continue to serve the scientists who are striving to improve human health.